{
  "submitter" : "Reach",
  "model_relation" : "extension",
  "extracted_information" : {
    "interaction_type" : "transcribes",
    "negative_information" : false,
    "participant_b" : {
      "in_model" : true,
      "identifier" : "uniprot:P04626",
      "entity_text" : "HER2",
      "entity_type" : "gene"
    },
    "hypothesis_information" : false,
    "context" : {
      "CellLine" : [ "cellosaurus:CVCL_1K15" ],
      "Species" : [ "taxonomy:9606" ],
      "TissueType" : [ "tissuelist:TS-0649" ],
      "CellType" : [ "cl:CL:0000623" ]
    }
  },
  "verbose_text" : "HER2 overexpression occurs in ~ 10-20% of all invasive ductal mammary carcinomas of no special type (NST) and these are treated with trastuzumab, which is a monoclonal anti-HER2 antibody.",
  "reading_complete" : "2020-08-04T12:27:11Z",
  "reader_type" : "machine",
  "reading_started" : "2020-08-04T12:24:52Z",
  "trigger" : "overexpression",
  "evidence" : [ "HER2 overexpression" ],
  "pmc_id" : "7105615",
  "score" : 0
}